March 2026 digest

Beyond the “All-TH2” Paradigm in Atopic Dermatitis

For more than two decades, atopic dermatitis (AD) has largely been interpreted through the framework of type-2 immunity. IL-4, IL-13, IgE, and eosinophils became the canonical pathway explaining disease pathogenesis and guiding therapeutic development. The remarkable clinical success of IL-4/IL-13 blockade has reinforced this paradigm. Yet both the biology and targeted therapy of AD increasingly suggest that the “all-TH2” model is incomplete.

A recent Nature study (DOI: 10.1038/s41586-026-10162-x) examining early-life immune programming offers a provocative developmental perspective. In neonatal mice, allergen exposure in the skin triggers a transient dendritic-cell state that drives local IL-23–γδT17 inflammation, preceding classical TH2 sensitization. In this model, early skin inflammation functions as an immunological priming event, shaping later allergic responses.

However, immune ontogeny alone cannot explain the striking rise of AD observed over recent decades. One of the most consistent features of the AD epidemic is its association with environmental factors that affect the skin barrier. Increased access to water, frequent washing, detergents, surfactants, and cosmetic products have profoundly altered the chemical ecology of the stratum corneum in modern societies. At the same time, genetic factors such as filaggrin deficiency continue to confer strong susceptibility in certain populations, particularly those living at higher latitudes with lower ultraviolet exposure.

These observations suggest that AD may emerge from the convergence of three interacting forces: barrier vulnerability (genetic or developmental), environmental barrier stress (detergents, hygiene practices, urban exposures), and early-life immune programming.

Barrier disruption permits the penetration of allergens and microbial signals into the epidermis. Early-life immune circuits may then determine how these signals are interpreted by the developing immune system. In this broader framework, the skin is not merely a passive barrier but an active interface between environment and immune development.

For clinicians and researchers, this perspective reinforces the importance of prevention strategies centered on the skin barrier—particularly during infancy, when both barrier function and immune programming remain highly plastic. Importantly, the window of prevention may even begin before birth. Maternal environment, microbiome, nutrition, and metabolic health influence fetal immune development and may shape early inflammatory trajectories.

Practically, protecting the infant epidermis, minimizing unnecessary chemical irritation, and identifying individuals with intrinsic barrier vulnerability may be as important as targeting immune pathways.

Type-2 inflammation remains central to the clinical expression and treatment of AD. But understanding how barrier ecology and immune ontogeny interact may ultimately be key to addressing the deeper challenge: not only how to treat atopic dermatitis, but how to prevent it.

In a Nutshell

---

#StayInformed: